What are the FDA warnings about using horse paste ivermectin for COVID-19 (2020–2022)?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
From 2020 through 2022 the U.S. Food and Drug Administration consistently warned that ivermectin is not authorized or approved to prevent or treat COVID‑19 and cautioned strongly against people using veterinary formulations — notably “horse paste” — because of documented poisonings and the risk of serious adverse effects [1] [2]. Those warnings were grounded in mounting clinical trial evidence showing lack of benefit for COVID‑19, and in reports of increased calls to poison control and hospitalizations after self‑medication with animal products [3] [4].
1. The FDA’s core message: not approved for COVID‑19 and don’t self‑medicate
The FDA repeatedly stated that no formulation of ivermectin had been authorized or approved to prevent or treat COVID‑19 in humans or animals, urging people not to take ivermectin products unless prescribed for an FDA‑approved use and obtained from a legitimate pharmacy [1] [5]. The agency made short, memorable warnings — including a viral tweet — highlighting that veterinary products are not safe for human use and that overdoses can cause serious outcomes from dizziness and seizures to coma or death [6] [1].
2. Documented harms the FDA cited and public‑health ripple effects
The FDA’s consumer updates and allied public‑health agencies flagged concrete harms: rising poison center calls, cases requiring hospitalization after ingesting animal ivermectin, and a range of toxicity symptoms including nausea, vomiting, neurologic dysfunction and severe liver injury [4] [3] [1]. Several news outlets and state poison centers reported individuals hospitalized after taking horse dewormer paste or injectable cattle products, which the FDA used as part of its rationale for urgent public warnings [6] [7].
3. Why “horse paste” and other animal formulations are especially risky
Animal ivermectin products are formulated at much higher concentrations and in different vehicles (pastes, pour‑ons, injectables) intended for large animals, so dosing and excipients differ from human tablets or topical formulations; the FDA and other medical sources stressed that those differences make animal products potentially highly toxic to people [2] [5]. Vendors’ dosing marks (e.g., per 200 lb on paste syringes) and non‑pharmaceutical fillers raised additional safety concerns documented in FDA communications and secondary reporting [5] [8].
4. Efficacy claims vs. clinical evidence: why the FDA urged caution
Early laboratory work showed ivermectin inhibited SARS‑CoV‑2 in vitro, which fueled interest, but the FDA pointed out that in‑cell studies do not translate into safe, effective human doses; larger randomized clinical trials completed through 2022 failed to show meaningful clinical benefit for COVID‑19, underpinning the FDA’s stance that ivermectin is not an appropriate COVID‑19 treatment [9] [10] [3]. The agency also referenced ongoing trials but maintained that available human data did not support use outside approved indications [1] [10].
5. Information battles, phrasing disputes and alternate perspectives
Some advocates and media outlets framed the FDA’s warnings as “recommendations” after legal filings, and conservative outlets claimed that phrasing revealed a policy shift — a characterization FactCheck.org found misleading because it did not change the underlying science‑based position that ivermectin isn’t authorized for COVID‑19 [4]. Meanwhile, proponents pointed to in‑vitro results and selective early studies; the FDA and mainstream clinical guideline bodies countered with later randomized trials and safety incident data to justify sustained warnings [9] [10].
6. Bottom line: practical implications taken from FDA communications
Between 2020 and 2022 the FDA’s communications were consistent and multifaceted: ivermectin is not approved for COVID‑19, animal ivermectin in particular can be dangerous or deadly to humans, and clinical evidence does not support its use for COVID‑19 — messages reinforced by poison‑control data, news reporting of hospitalizations, and the failure of clinical trials to show benefit [1] [4] [3]. Reporting and legal quibbles altered the tone in some outlets, but the factual core of the FDA’s warning remained unchanged in the supplied sources [4].